Share repurchase: the Company repurchased 550,229 shares of its Common Stock from Tactic Pharma at the public offering price less underwriting discounts and commissions, using $35 million of September 2025 offering proceeds.
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Chandler D. Robinson
Also a director
Chief Executive Officer, Director
|
42 | Not stated | $10,637,821 | |
|
Quan A. Vu
Chief Financial Officer, Secretary and Treasurer
|
54 | Not stated | $2,101,314 | |
|
Andrew J. Cittadine
Chief Operating Officer
|
54 |
Since 2021
5 years
|
$4,706,431 | |
|
Susan Rodriguez
CCSO
Title from the Form 4 dated Mar 2, 2026
|
Not stated |
Since 2026
this year
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Share repurchase: the Company repurchased 550,229 shares of its Common Stock from Tactic Pharma at the public offering price less underwriting discounts and commissions, using $35 million of September 2025 offering proceeds.
Loading...